摘要
背景:20世纪90年代,β干扰素和醋酸玻璃酸酯被引入治疗复发性多发性硬化症。这些药物有明显的疗效记录,安全,虽然它们需要经常通过注射给药,而且只部分有效。对一线治疗无效患者的治疗优化对于取得最好的长期结果是必不可少的。切换到最近批准的紧急治疗是一种策略,以考虑治疗的病人有次优的反应。 目的:综述目前多发性硬化疾病修饰治疗的作用机制、临床疗效和安全性概况,包括高效的单抗AN。滴度或方便口服治疗,并特别注重聚乙二醇化干扰素β1a的配方。 方法:通过PubMed和Clinicaltrials.gov的文献检索,回顾了近年来有关多发性硬化治疗的文献和人类临床试验。 结果和结论:虽然第一线干扰素β具有良好的优势t注射给药。通过β干扰素与化学活化的聚乙二醇反应,获得了较少的剂量和更好的药理性能。但条件是没有一种有效的治疗方法对所有的结果都显示出更好的效果,其在临床实践中的安全性是一个基本的问题,聚乙二醇化的干扰素β似乎能保持它的p。花边作为一种有竞争力的治疗选择。
关键词: 聚乙二醇干扰素β,聚乙二醇-干扰素-β,多发性硬化,紧急治疗,治疗策略,治疗优化,管理MS患者.
Current Medicinal Chemistry
Title:New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis
Volume: 25 Issue: 27
关键词: 聚乙二醇干扰素β,聚乙二醇-干扰素-β,多发性硬化,紧急治疗,治疗策略,治疗优化,管理MS患者.
摘要: Background: In the 1990s, the beta interferons and glatiramer acetate were introduced for treating relapsing-remitting multiple sclerosis. These medications have a demonstrated record of efficacy and safety, although they require frequent administration via injection and are only partially effective. The optimization of treatment in patients who do not respond adequately to this first-line therapy is essential for attaining the best long-term outcomes. Switching to the recently approved emergent therapies is a strategy to consider for treatment of patients with a suboptimal response.
Objective: This review summarizes the mechanisms of action, clinical benefits, and safety profiles of current multiple sclerosis disease-modifying therapies, including highly efficacious monoclonal antibodies or convenient oral therapies, and with a special focus on the pegylated interferon beta 1a formulation.
Methods: We reviewed the recent literature and human clinical trials on multiple sclerosis therapies by bibliographic search in PubMed and clinicaltrials.gov.
Results and Conclusion: Although the first-line interferon beta exhibits a favorable benefit-torisk profile, treatment compliance is compromised potentially due to its known adverse events and frequent injectable administration. Less frequent dosing and improved pharmacological properties have been achieved by reaction of interferon beta with chemically activated polyethylene glycol. Provided that none of the available therapies show better effectiveness for all outcomes and their safety in clinical practice is of a fundamental concern, the pegylated form of interferon beta seems to keep its place as a competitive therapeutic option.
Export Options
About this article
Cite this article as:
New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis, Current Medicinal Chemistry 2018; 25 (27) . https://dx.doi.org/10.2174/0929867325666180226105612
DOI https://dx.doi.org/10.2174/0929867325666180226105612 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Rat Model of Ischemic Enteritis: Pathogenic Importance of Enterobacteria, iNOS/NO, and COX-2/PGE2
Current Pharmaceutical Design Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design Therapeutic Agents for Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Pharmacogenomics of Breast Cancer Targeted Therapy: Focus on Recent Patents
Recent Patents on DNA & Gene Sequences Stem Cell Lineage Commitment by Electrical Fields and the Potential Application in Drug Discovery
Current Drug Metabolism Anti-inflammatory Effects of Rosuvastatin in Healthy Subjects: A Prospective Longitudinal Study
Current Pharmaceutical Design Application of Nanotechnology in Acupuncture
Current Nanoscience Therapeutic Targets to Raise HDL in Patients at Risk or with Coronary Artery Disease
Current Vascular Pharmacology Hemangiomas, Angiosarcomas, and Vascular Malformations Represent the Signaling Abnormalities of Pathogenic Angiogenesis
Current Molecular Medicine Safety Considerations in the Use of Ketorolac for Postoperative Pain
Current Drug Safety Molecular Biomarkers for Amyotrophic Lateral Sclerosis
Current Bioinformatics Host Immune Responses to Aeromonas Virulence Factors
Current Immunology Reviews (Discontinued) Lipid A Biosynthesis of Multidrug-Resistant Pathogens - A Novel Drug Target
Current Pharmaceutical Design Psychiatric Disorders Associated with FXTAS
Current Psychiatry Reviews Hydrogen Sulfide and Endothelial Dysfunction: Relationship with Nitric Oxide
Current Medicinal Chemistry MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Current Pharmaceutical Design Editorial (Thematic Issue: Vascular Dysfunction in Obesity and Insulin Resistance)
Current Vascular Pharmacology Optical Image-Guided Cancer Therapy
Current Pharmaceutical Biotechnology Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design